Squamous cell carcinoma - Карциномаҳои Ҳуҷайраҳои Сквамоз
☆ Дар натиҷаҳои соли 2022 Stiftung Warentest аз Олмон, қаноатмандии истеъмолкунандагон аз ModelDerm нисбат ба машваратҳои пулакии телетиб танҳо каме пасттар буд.
Squamous cell carcinoma well differentiated ― Кератози актинии ҳамшафат мушоҳида мешавад.
References
Squamous cell carcinoma (SCC) дуюмин саратони пӯст дар Иёлоти Муттаҳида пас аз basal cell carcinoma аст. Он одатан аз захмҳои пеш аз саратон бо номи actinic keratosis оғоз мешавад ва метавонад ба дигар қисмҳои бадан паҳн шавад. Сабаби асосии он таъсири радиатсияи ултрабунафш (UV) аз офтоб аст, ки бо мурури замон ҷамъ мешаванд. Табобат одатан хориҷ кардани ҷарроҳиро дар бар мегирад, махсусан барои SCC дар сар ва гардан. Табобати радиатсионӣ як вариант барои беморони калонсол ё онҳое, ки ҷарроҳӣ карда наметавонанд. Иммуносупрессия хатари пайдоиши SCC меафзояд. Ҳарчанд кам, SCC метавонад паҳн шавад, махсусан дар беморони дорои системаи иммунии заиф. Муоинаи мунтазам ва муҳофизати офтоб барои онҳое, ки дорои SCC мебошанд, муҳиманд.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) дуюмин саратони маъмултарин дар байни одамон аст ва шумораи он меафзояд. Гарчанде ки CSCC одатан рафтори хуби клиникиро нишон медиҳад, он метавонад ҳам дар маҳал ва ҳам ба дигар қисмҳои бадан паҳн шавад. Олимон роҳҳои мушаххасеро, ки дар рушди CSCC иштирок мекунанд, муайян карданд, ки ба табобатҳои нав оварда мерасонанд. Миқдори зиёди мутатсияҳо ва зиёд шудани хатар дар беморони гирифтори масуният боиси рушди иммунотерапия гардид. Ин барраси ба решаҳои генетикии CSCC ва усулҳои охирини табобат, ки ба молекулаҳои мушаххас ва системаи иммунӣ нигаронида шудаанд, баррасӣ мекунад.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Ташхис ва табобат
#Dermoscopy
#Skin biopsy